583843-92-9

Upstream product

• 583843-91-8 3'-O-benzyl-3-N-benzyloxymethyl-3'-C-methoxymethyloxymethyl-5'-O-(4,4'-dimethoxytrityl)thymidine 
• 724709-46-0 3-N-(benzyloxymethyl)-3'-C-((methoxymethoxy)methyl)-5'-O-tritylthymidine 
• 724709-45-9 3-N-(benzyloxymethyl)-3'-C-(hydroxymethyl)-5'-O-tritylthymidine 
• 583843-99-6 3'-C-(hydroxymethyl)-5'-O-tritylthymidine 
• 724709-47-1 3'-O-benzyl-3-N-(benzyloxymethyl)-3'-C-((methoxymethoxy)methyl)-5'-O-tritylthymidine 
• 131607-35-7 3'-deoxy-3'-C-methylidene-5'-O-(triphenylmethyl)thymidine 
• 3587-60-8 Benzyloxymethyl chloride 

Downstream Products

• 583843-95-2 3',5'-di-O-benzyl-3-N-(benzyloxymethyl)-4'-C-(hydroxymethyl)-3'-C-((methoxymethoxy)methyl)thymidine 
• 583843-97-4 3'-O,5'-O-dibenzyl-3-N-benzyloxymethyl-3'-C,4'-C-[methylenebis(oxymethyl)]thymidine 
• 583843-94-1 3'-O-benzyl-3-N-(benzyloxymethyl)-4'-C-(hydroxymethyl)-3'-C-((methoxymethoxy)methyl)thymidine 
• 950755-37-0 C₃₅H₃₈N₂O₇ 
• 950755-36-9 3',5'-di-O-benzyl-3-N-(benzyloxymethyl)-3'-C-(2-hydroxyethyl)-4'-C-(p-toluenesulfonyloxymethyl)thymidine 
• 1054594-66-9 C₄₂H₄₄N₂O₁₀S 
• 1054594-64-7 3',5'-di-O-benzyl-3-N-(benzyloxymethyl)-3'-C-(2-methoxyethenyl)-4'-C-(p-toluenesulfonyloxymethyl)thymidine 
• 1054594-62-5 C₄₁H₄₂N₂O₁₀S 
• 950755-34-7 3',5'-di-O-benzyl-3-N-(benzyloxymethyl)-3'-C-(hydroxymethyl)-4'-C-(p-toluenesulfonyloxymethyl)thymidine 
• 950755-33-6 3',5'-di-O-benzyl-3-N-(benzyloxymethyl)-3'-C-((methoxymethoxy)methyl)-4'-C-(p-toluenesulfonyloxymethyl)thymidine 
• 1054594-57-8 C₅₇H₆₀N₂O₁₁ 
• 1054594-55-6 C₅₀H₅₄N₂O₁₁ 
• 583843-93-0 (2S,3R,5R)-3-Benzyloxy-5-(3-benzyloxymethyl-5-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-3-methoxymethoxymethyl-tetrahydro-furan-2-carbaldehyde 

Relevant academic research and scientific papers

Development of a novel nucleoside analogue with S-type sugar conformation: 2′-deoxy-trans-3′,4′-bridged nucleic acids

Two novel trans-3′,4′-bridged nucleic acid (trans-3′,4′-BNA) monomers, one with a 3,5,8-trioxabicyclo[5.3.0]decane structure and the other with a 4,7-dioxabicyclo[4.3.0]nonane structure, were successfully synthesized from thymidine. The locked trans-fused ring structures of the nucleoside analogues were confirmed by X-ray crystallography, which also indicated that their furanose rings had a typical S-type conformation involving C2′-endo or C3′-exo sugar puckering, respectively, and the same ring conformation as that observed in the B-type helical structure of the DNA duplex.

NUCLEOSIDE ANALOGUES WHOSE SUGAR MOIETIES ARE BOUND IN S-FORM AND OLIGONUCLEOTIDE DERIVATIVES COMPRISING NUCLEOTIDE ANALOGUES THEREOF

Compounds of the following general formula (1) and salts thereof: where A represents an alkylene group having 1 to 2 carbon atoms, etc.; B represents an aromatic heterocyclic group which may have a substituent, etc.; R1 and R2 each represent a hydrogen atom, a protective group for a hydroxyl group for synthesis of nucleic acid, a phosphate group, or -P(R4)R5 [where R4 and R5 are the same or different, and each represent a hydroxyl group, a hydroxyl group protected with a protective group for synthesis of nucleic acid, a mercapto group, a mercapto group protected with a protective group for synthesis of nucleic acid, etc.]; and R3 represents a hydrogen atom, a halogen atom, a hydroxyl group, a hydroxyl group protected with a protective group for synthesis of nucleic acid, etc. These compounds are useful for producing oligonucleotide analogues useful for the antisense method, antigene method, etc., and for producing their intermediates.

Synthesis and conformation of a novel bridged nucleic acid having a trans-fused 3,5,8-trioxabicyclo[5.3.0]decane structure

A novel bridged nucleic acid analogue, 2′-deoxy-trans-3′, 4′-BNA thymine monomer, was successfully synthesized. An ab initio calculation and X-ray structure analysis revealed that the trans-fused bicyclo[5.3.0]decane structure of the 2′-deoxy-trans-3′,4′-BNA effectively constrained the sugar puckering in C2′-endo with appropriate γ, δ and χ angles.